Bdc-1001

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

BDC-1001 is an experimental drug currently under investigation for the treatment of colorectal cancer, particularly in patients with mutations or alterations in the Wnt/ -catenin pathway; its clinical efficacy and safety are still being evaluated in early-phase clinical trials.

Mechanism of Action

BDC-1001 is an investigational agent that targets the Wnt/ -catenin signaling pathway, which is often aberrantly activated in colorectal cancer; it inhibits ?-catenin-mediated transcription by binding to T-cell factor (TCF) proteins.

Side Effects

Hypertension; fatigue; nausea; vomiting

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04278144 Phase 1
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
United States, France, South Korea, Spain

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.